Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1986 1
1987 3
1990 1
1991 1
1992 2
1993 1
1994 5
1995 3
1996 1
1997 1
1998 2
2000 4
2001 3
2003 2
2004 1
2006 3
2007 4
2011 1
2012 2
2013 4
2014 1
2015 2
2016 2
2017 4
2018 3
2019 3
2020 3
2021 8
2022 7
2023 6
2024 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database.
Nagasu H, Yano Y, Kanegae H, Heerspink HJL, Nangaku M, Hirakawa Y, Sugawara Y, Nakagawa N, Tani Y, Wada J, Sugiyama H, Tsuruya K, Nakano T, Maruyama S, Wada T, Yamagata K, Narita I, Tamura K, Yanagita M, Terada Y, Shigematsu T, Sofue T, Ito T, Okada H, Nakashima N, Kataoka H, Ohe K, Okada M, Itano S, Nishiyama A, Kanda E, Ueki K, Kashihara N. Nagasu H, et al. Among authors: itano s. Diabetes Care. 2021 Nov;44(11):2542-2551. doi: 10.2337/dc21-1081. Epub 2021 Sep 30. Diabetes Care. 2021. PMID: 34593566 Free PMC article.
A case series of Fabry diseases with CKD in Japan.
Yusei O, Nagasu H, Nakagawa N, Terawaki S, Moriwaki T, Itano S, Kishi S, Sasaki T, Kashihara N, Otomo T. Yusei O, et al. Among authors: itano s. Clin Exp Nephrol. 2024 May;28(5):404-408. doi: 10.1007/s10157-023-02439-6. Epub 2024 Jan 9. Clin Exp Nephrol. 2024. PMID: 38193991 Free PMC article.
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.
Shimose S, Saeki I, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Naganuma A, Nishina S, Otsuka M, Kawashima H, Takayama T, Takami T, Kawaguchi T. Shimose S, et al. Among authors: itano s. Oncol Lett. 2024 Jun 25;28(2):397. doi: 10.3892/ol.2024.14530. eCollection 2024 Aug. Oncol Lett. 2024. PMID: 38979550 Free PMC article.
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.
Saeki I, Shimose S, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Kanayama Y, Naganuma A, Nishina S, Otsuka M, Kobara H, Kawashima H, Takayama T, Kawaguchi T, Yamasaki T, Takami T; Hepatology InVestigator Experts in Japan (HIVE-J) Study Group. Saeki I, et al. Among authors: itano s. PLoS One. 2024 Sep 25;19(9):e0311084. doi: 10.1371/journal.pone.0311084. eCollection 2024. PLoS One. 2024. PMID: 39321197 Free PMC article.
Guidelines for clinical evaluation of chronic kidney disease in early stages : AMED research on regulatory science of pharmaceuticals and medical devices.
Sugawara Y, Kanda E, Hamano T, Itano S, Okada H, Tomori K, Watanabe Y, Asakura W, Isaka Y, Iseki K, Usui T, Suzuki Y, Tanaka M, Nishimura R, Fukami K, Matsushita K, Wada J, Watada H, Ueki K, Kashihara N, Nangaku M; Research Working Group for Establishing Guidelines for Clinical Evaluation of Chronic Kidney Disease. Sugawara Y, et al. Among authors: itano s. Clin Exp Nephrol. 2024 Sep;28(9):847-865. doi: 10.1007/s10157-024-02514-6. Epub 2024 Jul 6. Clin Exp Nephrol. 2024. PMID: 38970650 Free PMC article.
89 results